Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FATE vs TAK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TAK Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–1 Matrix Metrics)

TAK Overall Winner 6-Pillar Tally: FATE 1 – 5 TAK Matrix Metrics: FATE 1 – 8 TAK

As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Fate Therapeutics, Inc. (FATE) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). FATE carries a Unified Composite Score of 43.0/100 (HOLD) at $1.12 (N/M Forward P/E, -1495.4% operating margin), whereas TAK carries 48.0/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin).

  • Technical & Structure Timing Caution: FATE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 20.6); meanwhile TAK trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 72.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FATE vs TAK
FATE NASDAQ
Fate Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$1.12
-12.5% 1D
Market Cap $162.9M
TTM Revenue $6.5M
Forward P/E N/M
Beta / 30D Vol 2.16β · 104% Vol
Unified Composite Score
43.0 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.8%), weak momentum, RSI 21
RSI-14: 20.6 · SMA20: $1.89 · SMA50: $2.13
TAK NYSE Head-to-Head Winner
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
TTM Revenue $25.7B
Forward P/E 12.7x
Beta / 30D Vol -0.02β · 22% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 43.0 Fund 44.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.9% over 20 days), RSI 72
RSI-14: 72.3 · SMA20: $20.71 · SMA50: $19.46

6-Pillar Scorecard Institutional Category Breakdown (FATE 1 – 5 TAK)

Columns: Metric · FATE · TAK
1. Valuation Multiples TAK
Forward P/E N/M 12.7x
Trailing P/E N/M N/M
PEG Ratio N/M 0.47x
EV / Revenue 29.8x 2.6x
2. Growth & Scale FATE
Revenue Growth (YoY) +9.2% +6.7%
Earnings Growth (YoY) +0.0% -9.8%
TTM Revenue (USD) $6.5M $25.7B
Market Cap $162.9M $67.5B
3. Profitability & Quality TAK
Gross Margin N/A 64.8%
Operating Margin -1495.4% 16.6%
Net Profit Margin 0.0% 0.9%
Return on Equity (ROE) -60.8% 0.6%
4. Balance Sheet & Cash Flow TAK
Cash Generation (TTM) -$107M $7.48B EBITDA
Cash Flow Margin N/A 29.1% EBITDA Mgn
Net Cash / Leverage $31M Net Debt (0.56x D/E) $14.68 Book/Sh · 0.6% ROE
Dividend Yield None (0.00%) 2.92%
5. Options & Positioning TAK
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 169.0% (20th %ile) 22.4% (5th %ile)
Put/Call OI Skew 1.52x (Put-Skewed) Thin ADR Chain
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat TAK
OpEx & R&D Intensity N/A 48.2% of Rev ($12.4B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FATE (1) vs TAK (8)
Institutional Metric FATE TAK Criterion Row Edge
Market Capitalization
Scale
$162.9M $67.5B Larger Scale TAK
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M 12.7x Lower Multiple TAK
Revenue Growth (YoY)
Growth
+9.2% +6.7% Higher Growth FATE
Operating Margin (TTM)
Profitability
-1495.4% 16.6% Higher Margin TAK
Net Profit Margin
Profitability
0.0% 0.9% Higher Margin TAK
Return on Equity (ROE)
Capital Efficiency
-60.8% 0.6% Higher ROE TAK
52-Week Range Position
Momentum
8% ($1–$3) 97% ($14–$22) Stronger Trend TAK
Beta / 30D Volatility
Risk Regime
2.16β · 104% Vol -0.02β · 22% Vol Lower Realized Risk TAK
Unified Institutional Score
Composite Signal
43.0 / 100 (HOLD) 48.0 / 100 (HOLD) Higher Composite TAK
Trailing 12M Revenue (USD)
Operating Scale
$6.5M $25.7B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 64.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 29.8x EV/Rev 0.47x PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$107M ($31M Net Debt (0.56x D/E)) $7.48B EBITDA ($14.68 Book/Sh · 0.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TAK +47.32 pp
FATE: -37.43% · TAK: +9.89%
3M Horizon TAK +76.0 pp
FATE: -56.25% · TAK: +19.75%
6M Horizon TAK +65.71 pp
FATE: -35.26% · TAK: +30.45%
1Y Horizon TAK +38.92 pp
FATE: +12.87% · TAK: +51.79%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FATE vs TAK. Trailing 12-month operating profitability (FATE -1495.4% vs TAK 16.6%) and valuation multiples (FATE N/M vs TAK 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.

FATE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.5M
Gross MarginN/A
Op. Margin-1495.4%
ROE / Fwd P/E-60.8% · N/M
TAK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$25.7B
Gross Margin64.8%
Op. Margin16.6%
ROE / Fwd P/E0.6% · 12.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FATE BREAKDOWN
118d in phase · OBV DISTRIBUTION
Current IV 169.0%
IV Percentile 20th %ile
Put/Call OI Skew 1.52x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact FATE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.4%
IV Percentile 5th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FATE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $162.9M market capitalization and -1495.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TAK Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment 48.2% of Rev ($12.4B)
90D Engineering Disclosures 0 Published

Investor FAQ FATE vs TAK Key Questions & Quantitative Answers

As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Fate Therapeutics, Inc. (FATE) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). FATE carries a Unified Composite Score of 43.0/100 (HOLD) at $1.12 (N/M Forward P/E, -1495.4% operating margin), whereas TAK carries 48.0/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin). Technical & Structure Timing Caution: FATE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 20.6); meanwhile TAK trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 72.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FATE leads the Growth & Scale pillar: FATE posts +9.2% YoY revenue growth and +0.0% YoY earnings growth on $6.5M TTM revenue (N/A gross margin, -1495.4% operating margin), compared with TAK at +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin). On trailing 12-month operating scale, FATE generates $6.5M in USD-normalized revenue versus $25.7B for TAK. In operating R&D and SG&A reinvestment, FATE deploys N/A (0 90-day corporate R&D disclosures) versus 48.2% of Rev ($12.4B) (0 disclosures) for TAK.

TAK screens cheaper on headline valuation multiples. FATE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.8x EV/Revenue (unreported FCF margin), whereas TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FATE (-60.8% ROE) versus TAK (0.6% ROE) capital efficiency.

In options market volatility and institutional positioning, FATE carries 169.0% implied volatility (20th %ile, Compressed (<25th %ile)), a 1.52x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.16β · 104% Vol realized risk). By comparison, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.